Table 5. ORR and MRD based on prior... | American Society of Hematology

Table 5.

ORR and MRD based on prior treatment history

Subgroup	ORR*		MRD-negative rate (10⁻⁵)†
Subgroup	Patients in group, n % Patients in group, n %
All response evaluable	82	84	11	36
Refractory to lenalidomide	48	79	5	20
Lenalidomide exposed but not refractory	30	90	4	50
Refractory to bortezomib	25	84	26	8
Refractory to IMiD	53	77	5	20
IMiD exposed but not refractory	29	97	6	50
Refractory to PI and IMiD	24	83	2	0
Cytogenetic risk‡
High§	13	69	3	67
Standard	52	90	6	33

Subgroup	ORR*		MRD-negative rate (10⁻⁵)†
Subgroup	Patients in group, n % Patients in group, n %
All response evaluable	82	84	11	36
Refractory to lenalidomide	48	79	5	20
Lenalidomide exposed but not refractory	30	90	4	50
Refractory to bortezomib	25	84	26	8
Refractory to IMiD	53	77	5	20
IMiD exposed but not refractory	29	97	6	50
Refractory to PI and IMiD	24	83	2	0
Cytogenetic risk‡
High§	13	69	3	67
Standard	52	90	6	33

Data are based on a computerized algorithm.

Of the 27 patients who achieved CR or better, 11 received MRD testing.

Biomarker risk-evaluable population.

Includes patients who have del17p, t(14;16), t(4;14) or a combination of these by fluorescence in situ hybridization or karyotype.